skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: What is your opinion on EVGO, it came out as an SPAC?
Read Answer Asked by OSCAR on July 08, 2021
Q: It has been awhile that a question has been asked about this company.

It has been breaking out technically.

Can you provide a fundamental update of this company. How does the future look for this company and do you have any opinion on the c-suite here.

Would you recommend for a TFSA?

Thanks for all you do!!!
Read Answer Asked by Thomas on July 08, 2021
Q: UEX is moving. It was 50 cents not too long ago and in about a month it dropped to 38 cents today. Can you please provide me with the most accurate website depicting the live price for uranium?What do you think about the future of this company and the supply and demand of uranium. You think UEX and uranium spot price will move alot over the summer? Or will it drop quickly over the summer?
Read Answer Asked by Adrian on July 07, 2021
Q: July 2nd I asked if NEXE was a buy sell or hold . your reply ,was that you do not give that type advice. you did not give that same answer today about a similar question regarding STOR why??????? I will ask in a different way ___ my break even price on NEXE is 1.37 other sites have said this will go to .92 cents is this 5i opinion; is this worth keeping in hope that their wrong
Read Answer Asked by gary on July 07, 2021
Q: Gritstone Bio (GRTS) is a small, early-stage biotech company to which Gilead Sciences has provided some funding under an agreement announced on Feb 1, 2021:

"Under the terms of the agreement, Gilead will make a $60 million payment at closing, consisting of a $30 million upfront cash payment and a $30 million equity investment at a premium. Gilead will be responsible for conducting a Phase 1 study for the HIV-specific therapeutic vaccine and holds an exclusive option under the collaboration to obtain an exclusive license to develop and commercialize the HIV-specific therapeutic vaccine beyond Phase 1. Gritstone is also eligible to receive up to an additional $725 million if the option is exercised and if certain clinical, regulatory and commercial milestones are achieved, as well as mid single-digit to low double-digit tiered royalties on net sales upon commercialization."

GRTS share price has established a baseline after falling steadily since the funding announcement. Presumably Gilead did some due diligence before investing its own money, but the stock price could go to zero if Gilead walks away. However, it could also soar if the trials are successful. Would you consider GRTS to be a worthwhile speculative buy? What has been your experience of investing in early-stage biotech companies that have drawn the attention of Big Pharma?
Read Answer Asked by David on July 07, 2021
Q: Ah! The widow and orphan stock.
What do you think? After all these years of never being able to gain traction, is now their time?
Just like nvdia when it did nothing for years and then became the darling of the street. Been burnt twice with Sierra but I sense a huge turnaround with 5G or a buyout!
Peter: your opinion! Thanks.
Read Answer Asked by Helen on July 07, 2021
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!